Category: Cardiovascular - page 17

PARADIGM-HF Trial: Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2014, Sacubitril-valsartan vs Enalapril in HF, NEJM. PARADIGM-HF Trial Summary The PARADIGM HF trial randomized 8442 patients with NYHA Class II, III or IV heart failure and a reduced ejection fraction of 40% or less to receive either 200 mg of LCZ696 (which consists of sacubitril and valsartan) or enalapril in a 1:1 ratio, in..

Read more

RENAAL Trial: Losartan in Patients with Type 2 Diabetes and Nephropathy

Source: NEJM RENAAL Trial Key Points1. Losartan was found to have significant reno-protective role in patients with type II diabetes and nephropathy.2. Losartan did not affect mortality in this patient population.3. Proteinuria significant improved in patients taking losartan compared to placebo.4. The IDNT trial tested irbesartan and reported similar renoprotective role in diabetic nephropathy. Guideline Recommendations based on RENAAL Trial: The..

Read more

SPRINT Trial: Intensive versus Standard Blood Pressure Control

The SPRINT trial study was an important leap towards tighter blood pressure control in patients who had a history of cardiovascular disease and were at high risk of recurrent event but with no history of stroke or diabetes. Guidelines update based on SPRINT trial The 2017 ACC/AHA update on hypertension recommended: For patients with Stable coronary artery..

Read more